Australian & New Zealand Childrens Haematology/Oncology Group

Clinical Trials

LINES: European Low and Intermediate Risk Neuroblastoma (Phase III SIOPEN study)


Status: Closed to Recruitment | NSW , VIC , WA

The treatment and prognosis (chance of cure) for a child with neuroblastoma is assessed by tests done at time of diagnosis. These tests include a biopsy of the tumour, special molecular tests on the tumour tissue, and investigations to determine whether the tumour has spread and if so, where.  The results of all these tests are then used to decide the “stage” of the tumour (defined by its extent of spread) and the disease “risk” (the chance of disease recurrence).

This study is being done to establish the best treatment for children with neuroblastoma that has a low or intermediate risk of recurring. Different treatment will be given to children with low risk and intermediate risk disease and will vary depending on the tumour characteristics. This trial will determine which of the current treatments for low and intermediate risk neuroblastoma provides the best outcome.

Disease Stage: Newly diagnosed

Patient Age Range: 3 months – 18 years

Trial Sponsors:

  • International: SIOPEN
  • National: ANZCHOG

Read more at the Clinical Trial Registry 

ANZCHOG acknowledges the valuable support of LINES by the Children's Cancer Foundation